NEW YORK (GenomeWeb) – Deep Knowledge Ventures and Insilico Medicine today announced they have completed a milestone-based convertible bridge note agreement. 

The agreement is for an $800,000 convertible loan from Hong Kong-based Deep Knowledge, leading to a next funding round of at least $4 million, conditional on Insilico achieving certain R&D and corporate development milestones. They include the validation of Insilico's drug repurposing capabilities and the establishment by Baltimore-based Insilico of an office in Basel, Switzerland, the partners said. 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.